Patents by Inventor Jason Isaacson

Jason Isaacson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mononuclear cell derived NK cells
    Patent number: 11453862
    Abstract: Cord blood or peripheral blood NK cells are prepared from whole blood mononuclear cells without the need to isolate CD34+ hematopoietic stem cells or NK cells, and without the need for a feeder layer. Advantageously, the methods presented herein use an enrichment process that uses antiCD16 agonist antibodies, antiCD3 antibodies, and N-803. Moreover, contemplated processes are suitable for adaptation into a fully automated production process (GMP in a box).
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: September 27, 2022
    Assignee: ImmunityBio, Inc.
    Inventors: Rohit Duggal, Ranjeet Sinha, Wenzhao Li, Jason Isaacson, Karl Marquez, Patrick Soon-Shiong
  • CIML NK cells and Methods Therefor
    Publication number: 20210361711
    Abstract: Cytokine induced memory like (CIML) NK cells with enhanced cytotoxicity are presented. Most typically, the CIML NK cells are derived from a mononuclear cell fraction of peripheral blood or cord blood. In further contemplated aspects, the CIML NK cells are expanded and induced in a contained and automated production environment that substantially reduces operational complexity and production cost.
    Type: Application
    Filed: July 14, 2021
    Publication date: November 25, 2021
    Inventors: Rohit Duggal, Ranjeet Sinha, Wenzhao Li, Jason Isaacson, Patrick Soon-Shiong
  • Mononuclear Cell Derived NK Cells
    Publication number: 20210009954
    Abstract: Cord blood or peripheral blood NK cells are prepared from whole blood mononuclear cells without the need to isolate CD34+ hematopoietic stem cells or NK cells, and without the need for a feeder layer. Advantageously, the methods presented herein use an enrichment process that uses antiCD16 agonist antibodies, antiCD3 antibodies, and N-803. Moreover, contemplated processes are suitable for adaptation into a fully automated production process (GMP in a box).
    Type: Application
    Filed: February 20, 2020
    Publication date: January 14, 2021
    Inventors: Rohit Duggal, Ranjeet Sinha, Wenzhao Li, Jason Isaacson, Karl Marquez, Patrick Soon-Shiong
  • Mononuclear Cell Derived NK Cells
    Publication number: 20210009953
    Abstract: Cord blood or peripheral blood NK cells are prepared from whole blood mononuclear cells without the need to isolate CD34+ hematopoietic stem cells or NK cells, and without the need for a feeder layer. Advantageously, the methods presented herein use an enrichment process that uses antiCD16 agonist antibodies, antiCD3 antibodies, and N-803. Moreover, contemplated processes are suitable for adaptation into a fully automated production process (GMP in a box).
    Type: Application
    Filed: July 8, 2019
    Publication date: January 14, 2021
    Inventors: Rohit Duggal, Ranjeet Sinha, Wenzhao Li, Jason Isaacson, Karl Marquez, Patrick Soon-Shiong
  • CIML NK cells and Methods Therefor
    Publication number: 20210008107
    Abstract: Cytokine induced memory like (CIML) NK cells with enhanced cytotoxicity are presented. Most typically, the CIML NK cells are derived from a mononuclear cell fraction of peripheral blood or cord blood. In further contemplated aspects, the CIML NK cells are expanded and induced in a contained and automated production environment that substantially reduces operational complexity and production cost.
    Type: Application
    Filed: July 8, 2019
    Publication date: January 14, 2021
    Inventors: Rohit Duggal, Ranjeet Sinha, Wenzhao Li, Jason Isaacson, Patrick Soon-Shiong
  • CIML NK cells and Methods Therefor
    Publication number: 20210008112
    Abstract: Cytokine induced memory like (CIML) NK cells with enhanced cytotoxicity are presented. Most typically, the CIML NK cells are derived from a mononuclear cell fraction of peripheral blood or cord blood. In further contemplated aspects, the CIML NK cells are expanded and induced in a contained and automated production environment that substantially reduces operational complexity and production cost.
    Type: Application
    Filed: August 5, 2020
    Publication date: January 14, 2021
    Inventors: Rohit Duggal, Ranjeet Sinha, Wenzhao Li, Jason Isaacson, Patrick Soon-Shiong
  • Dual assay for evaluating activity and cytotoxicity of compounds in the same population of cells
    Publication number: 20050112551
    Abstract: Methods are provided for evaluating the activity and cytoxicity of a compound in the same population of cells. These dual activity/cytoxicity methods are amenable for use in a high-throughput format. Also provided are humanized Renilla luciferase genes useful for the dual activity/cytoxicity assays and for use in a variety of reporter constructs.
    Type: Application
    Filed: November 24, 2003
    Publication date: May 26, 2005
    Inventors: Wade Blair, Joan Cao, Jason Isaacson, Amy Patick